Vaginal HRT Pessary vs Cream for Perimenopause: Which Local Oestrogen Is Best?

Understanding Local Vaginal Oestrogen

Vaginal oestrogen is a form of hormone therapy applied directly to the vaginal tissues rather than absorbed systemically through skin patches, gels, or tablets. Because it acts locally, the doses used are very low and only a tiny fraction enters the bloodstream, making it suitable for many women who cannot or choose not to use systemic HRT. It is prescribed to treat genitourinary syndrome of menopause (GSM), a cluster of symptoms caused by falling oestrogen that includes vaginal dryness, burning, irritation, painful sex, urinary urgency, and recurrent urinary tract infections. These symptoms affect a large proportion of women in perimenopause and beyond and tend to worsen over time without treatment. Local oestrogen comes in several forms: pessaries (small tablets or capsules inserted into the vagina), creams applied with an applicator, rings that sit inside the vagina and release oestrogen slowly, and vaginal gels. This article focuses on the two most commonly prescribed and used forms: pessaries and creams.

How Each Form Works and Differs

Pessaries are small, solid or soft-gel formulations inserted directly into the vagina using a small applicator or a fingertip. They dissolve or absorb over several hours, delivering oestrogen to the local tissue. Common branded examples include Vagifem (estradiol pessary) and Imvaggis (estriol pessary). They are typically used daily for two weeks initially, then reduced to twice weekly for long-term maintenance. Creams such as Ovestin (containing estriol) or Premarin are applied inside the vagina and around the vulval area using a measured applicator. Creams can also be applied directly to the external vulval tissues, making them more flexible for women whose discomfort is primarily external rather than internal. The active ingredient differs between products: most pessaries use estradiol, while many creams use estriol, a weaker oestrogen. Both are effective, but estriol has slightly lower potency, which some clinicians consider an advantage for women with a history of hormone-sensitive conditions, though evidence on safety is broadly similar for both forms at the low doses used locally.

Ease of Use and Practical Differences

Ease of use is one of the most common deciding factors for women choosing between these forms, and individual preference varies considerably. Pessaries are generally considered cleaner and more straightforward to use. The applicator positions the pessary correctly and there is minimal leakage or residue afterward. Once inserted, there is little to manage. Many women find this format preferable for ongoing twice-weekly use because it fits easily into a routine without mess. Creams require loading an applicator with a measured dose, which can feel fiddlier, particularly initially. They can also feel messy, and some women notice cream residue. However, creams have a meaningful advantage for external application. Women experiencing vulval dryness, clitoral sensitivity, and discomfort at the vaginal opening, which is common during sex in perimenopause, can apply cream directly to those external areas without insertion. This versatility makes creams more practical when external symptoms are prominent. Some women use a pessary for internal use and a small amount of cream for external relief, combining both where cost permits.

Effectiveness and What Each Treats Best

Both forms are clinically effective for the core symptoms of GSM. Research consistently shows that local vaginal oestrogen, regardless of form, restores vaginal pH, increases natural lubrication, thickens vaginal tissue, and reduces the discomfort of penetrative sex. Multiple clinical guidelines including those from the British Menopause Society and the North American Menopause Society endorse local oestrogen as a first-line treatment for GSM. In terms of relative effectiveness, there is no strong evidence that pessaries or creams outperform each other when comparing internal vaginal symptoms. The difference becomes more pronounced for external symptoms, where cream applied to the vulva and clitoral hood is more practical than a pessary. Urinary symptoms including urgency, frequency, and recurrent UTIs also respond to local oestrogen, because oestrogen receptors in the urethra and bladder respond to the nearby application. Some women notice improvement in urinary symptoms within four to twelve weeks of consistent use, though full tissue restoration can take three to six months.

Systemic Absorption and Safety Concerns

A question many women ask is whether local vaginal oestrogen is safe for those who have been advised to avoid systemic hormones, for example after a history of breast cancer or blood clots. The evidence is reassuring but not entirely uniform. Systemic absorption from vaginal oestrogen is low, particularly at maintenance doses of twice weekly. Studies measuring blood oestrogen levels in women using vaginal pessaries or cream at standard doses typically show levels remaining within the postmenopausal reference range rather than rising to premenopausal levels. This is in marked contrast to systemic HRT, which significantly elevates circulating oestrogen. For most women without a hormone-sensitive cancer history, local vaginal oestrogen at maintenance doses does not require the same safety considerations as systemic HRT. For breast cancer survivors, guidance varies by oncologist and by the specific cancer type and treatment, so individual medical advice is essential. Estriol-containing products are sometimes preferred in this population because estriol has weaker oestrogenic activity, though the overall evidence on safety in cancer survivors is still evolving.

How to Choose and What to Discuss With Your Doctor